Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.
This table compares Taysha Gene Therapies and Zura Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Taysha Gene Therapies||N/A||-1,790.06%||-118.08%|
Risk and Volatility
Taysha Gene Therapies has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Taysha Gene Therapies||$9.60 million||43.03||-$166.01 million||($2.29)||-0.97|
|Zura Bio||N/A||N/A||$3.55 million||N/A||N/A|
Zura Bio has lower revenue, but higher earnings than Taysha Gene Therapies.
Institutional & Insider Ownership
25.9% of Taysha Gene Therapies shares are held by institutional investors. 2.3% of Taysha Gene Therapies shares are held by insiders. Comparatively, 15.8% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for Taysha Gene Therapies and Zura Bio, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Taysha Gene Therapies||0||4||8||0||2.67|
Taysha Gene Therapies presently has a consensus target price of $7.91, indicating a potential upside of 257.07%. Zura Bio has a consensus target price of $16.60, indicating a potential upside of 235.35%. Given Taysha Gene Therapies’ higher probable upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than Zura Bio.
Zura Bio beats Taysha Gene Therapies on 7 of the 11 factors compared between the two stocks.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.